Oppenheimer Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $65.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price boosted by Oppenheimer from $63.00 to $65.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Stock Down 3.9 %

NASDAQ TARS opened at $44.83 on Thursday. Tarsus Pharmaceuticals has a 52 week low of $15.60 and a 52 week high of $52.99. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00. The company has a quick ratio of 6.99, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a fifty day moving average of $37.84 and a two-hundred day moving average of $32.53.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Cowen AND Company LLC boosted its position in Tarsus Pharmaceuticals by 3.5% in the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after buying an additional 74,855 shares during the period. Jennison Associates LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after purchasing an additional 231,131 shares during the period. Assenagon Asset Management S.A. grew its stake in Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after purchasing an additional 77,825 shares in the last quarter. Finally, Ikarian Capital LLC raised its position in Tarsus Pharmaceuticals by 28.7% during the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after purchasing an additional 230,000 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.